ArticleKidney cancer (Clifton, Va.)2019

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048.

Thomas J Semrad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.